Human Schlafen 5 (SLFN5) is a regulator of motility and invasiveness of renal cell carcinoma cells

Antonella Sassano, Evangelos Mavrommatis, Ahmet Dirim Arslan, Barbara Kroczynska, Elspeth M. Beauchamp, Satya Khuon, Ten Leong Chew, Kathleen J. Green, Hidayatullah G. Munshi, Amit K. Verma, Leonidas C. Platanias

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We provide evidence that human SLFN5, an interferon (IFN)-inducible member of the Schlafen (SLFN) family of proteins, exhibits key roles in controlling motility and invasiveness of renal cell carcinoma (RCC) cells. Our studies define the mechanism by which this occurs, demonstrating that SLFN5 negatively controls expression of the matrix metalloproteinase 1 gene (MMP-1), MMP-13, and several other genes involved in the control of malignant cell motility. Importantly, our data establish that SLFN5 expression correlates with a better overall survival in a large cohort of patients with RCC. The inverse relationship between SLFN5 expression and RCC aggressiveness raises the possibility of developing unique therapeutic approaches in the treatment of RCC, by modulating SLFN5 expression.

Original languageEnglish (US)
Pages (from-to)2684-2698
Number of pages15
JournalMolecular and Cellular Biology
Volume35
Issue number15
DOIs
StatePublished - 2015

Fingerprint

Renal Cell Carcinoma
Matrix Metalloproteinase 1
Matrix Metalloproteinases
Interferons
Genes
Cell Movement
Survival
Therapeutics
Proteins

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Sassano, A., Mavrommatis, E., Arslan, A. D., Kroczynska, B., Beauchamp, E. M., Khuon, S., ... Platanias, L. C. (2015). Human Schlafen 5 (SLFN5) is a regulator of motility and invasiveness of renal cell carcinoma cells. Molecular and Cellular Biology, 35(15), 2684-2698. https://doi.org/10.1128/MCB.00019-15

Human Schlafen 5 (SLFN5) is a regulator of motility and invasiveness of renal cell carcinoma cells. / Sassano, Antonella; Mavrommatis, Evangelos; Arslan, Ahmet Dirim; Kroczynska, Barbara; Beauchamp, Elspeth M.; Khuon, Satya; Chew, Ten Leong; Green, Kathleen J.; Munshi, Hidayatullah G.; Verma, Amit K.; Platanias, Leonidas C.

In: Molecular and Cellular Biology, Vol. 35, No. 15, 2015, p. 2684-2698.

Research output: Contribution to journalArticle

Sassano, A, Mavrommatis, E, Arslan, AD, Kroczynska, B, Beauchamp, EM, Khuon, S, Chew, TL, Green, KJ, Munshi, HG, Verma, AK & Platanias, LC 2015, 'Human Schlafen 5 (SLFN5) is a regulator of motility and invasiveness of renal cell carcinoma cells', Molecular and Cellular Biology, vol. 35, no. 15, pp. 2684-2698. https://doi.org/10.1128/MCB.00019-15
Sassano, Antonella ; Mavrommatis, Evangelos ; Arslan, Ahmet Dirim ; Kroczynska, Barbara ; Beauchamp, Elspeth M. ; Khuon, Satya ; Chew, Ten Leong ; Green, Kathleen J. ; Munshi, Hidayatullah G. ; Verma, Amit K. ; Platanias, Leonidas C. / Human Schlafen 5 (SLFN5) is a regulator of motility and invasiveness of renal cell carcinoma cells. In: Molecular and Cellular Biology. 2015 ; Vol. 35, No. 15. pp. 2684-2698.
@article{232873fd403e469992bd61fea7ca257c,
title = "Human Schlafen 5 (SLFN5) is a regulator of motility and invasiveness of renal cell carcinoma cells",
abstract = "We provide evidence that human SLFN5, an interferon (IFN)-inducible member of the Schlafen (SLFN) family of proteins, exhibits key roles in controlling motility and invasiveness of renal cell carcinoma (RCC) cells. Our studies define the mechanism by which this occurs, demonstrating that SLFN5 negatively controls expression of the matrix metalloproteinase 1 gene (MMP-1), MMP-13, and several other genes involved in the control of malignant cell motility. Importantly, our data establish that SLFN5 expression correlates with a better overall survival in a large cohort of patients with RCC. The inverse relationship between SLFN5 expression and RCC aggressiveness raises the possibility of developing unique therapeutic approaches in the treatment of RCC, by modulating SLFN5 expression.",
author = "Antonella Sassano and Evangelos Mavrommatis and Arslan, {Ahmet Dirim} and Barbara Kroczynska and Beauchamp, {Elspeth M.} and Satya Khuon and Chew, {Ten Leong} and Green, {Kathleen J.} and Munshi, {Hidayatullah G.} and Verma, {Amit K.} and Platanias, {Leonidas C.}",
year = "2015",
doi = "10.1128/MCB.00019-15",
language = "English (US)",
volume = "35",
pages = "2684--2698",
journal = "Molecular and Cellular Biology",
issn = "0270-7306",
publisher = "American Society for Microbiology",
number = "15",

}

TY - JOUR

T1 - Human Schlafen 5 (SLFN5) is a regulator of motility and invasiveness of renal cell carcinoma cells

AU - Sassano, Antonella

AU - Mavrommatis, Evangelos

AU - Arslan, Ahmet Dirim

AU - Kroczynska, Barbara

AU - Beauchamp, Elspeth M.

AU - Khuon, Satya

AU - Chew, Ten Leong

AU - Green, Kathleen J.

AU - Munshi, Hidayatullah G.

AU - Verma, Amit K.

AU - Platanias, Leonidas C.

PY - 2015

Y1 - 2015

N2 - We provide evidence that human SLFN5, an interferon (IFN)-inducible member of the Schlafen (SLFN) family of proteins, exhibits key roles in controlling motility and invasiveness of renal cell carcinoma (RCC) cells. Our studies define the mechanism by which this occurs, demonstrating that SLFN5 negatively controls expression of the matrix metalloproteinase 1 gene (MMP-1), MMP-13, and several other genes involved in the control of malignant cell motility. Importantly, our data establish that SLFN5 expression correlates with a better overall survival in a large cohort of patients with RCC. The inverse relationship between SLFN5 expression and RCC aggressiveness raises the possibility of developing unique therapeutic approaches in the treatment of RCC, by modulating SLFN5 expression.

AB - We provide evidence that human SLFN5, an interferon (IFN)-inducible member of the Schlafen (SLFN) family of proteins, exhibits key roles in controlling motility and invasiveness of renal cell carcinoma (RCC) cells. Our studies define the mechanism by which this occurs, demonstrating that SLFN5 negatively controls expression of the matrix metalloproteinase 1 gene (MMP-1), MMP-13, and several other genes involved in the control of malignant cell motility. Importantly, our data establish that SLFN5 expression correlates with a better overall survival in a large cohort of patients with RCC. The inverse relationship between SLFN5 expression and RCC aggressiveness raises the possibility of developing unique therapeutic approaches in the treatment of RCC, by modulating SLFN5 expression.

UR - http://www.scopus.com/inward/record.url?scp=84936062406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936062406&partnerID=8YFLogxK

U2 - 10.1128/MCB.00019-15

DO - 10.1128/MCB.00019-15

M3 - Article

VL - 35

SP - 2684

EP - 2698

JO - Molecular and Cellular Biology

JF - Molecular and Cellular Biology

SN - 0270-7306

IS - 15

ER -